Levemir (insulin detemir rDNA origin) / Novo Nordisk - LARVOL DELTA

Hybrid closed loop in a residential setting: it takes a village but it is worth it (ESPE-ESE 2025) - "Despite being on basal bolus regimen with insulin aspart and detemir and wearing real-time continuous glucose monitoring, her glycaemic ranges were suboptimal (average sensor glucose 14.5mmol/L, GMI 9.6%, Time-in-Range 15%, Very High-Above-Range 57%, High-Above-Range 28%, HbA1c 61mmol/mol)...Our case suggests that HCL system together with a skilled diabetes MDT support offers promising benefits for residential use. Continued research is necessary to optimise the functionality of HCL system for this cohort."

Celiac Disease • Diabetes • Endocrine Disorders • Gastrointestinal Disorder • Hypoglycemia • Immunology • Metabolic Disorders • Rare Diseases • Type 1 Diabetes Mellitus

Localized Scleroderma in a Type 1 Diabetic Patient : A Case Report (ESPE-ESE 2025) - "Her medical history included an auto-immune hypothyroidism treated with 75 ug/day of levothyroxine...She was treated with insulin analogs: insulin detemir and aspart...The patient was started on methotrexate at 12.5 mg/week, and an insulin pump was proposed to obtain a better control of diabetes with reduced the number of injections. Conclusion The identification of localized scleroderma in a patient initially thought to have lipodystrophy highlights the importance of considering rare and atypical diagnoses in patients with diabetes as they can have a significant impact on diabetic control."

Case report • Clinical • Diabetes • Endocrine Disorders • Immunology • Lipodystrophy • Metabolic Disorders • Rare Diseases • Scleroderma • Systemic Sclerosis • Type 1 Diabetes Mellitus

Case of complete remission of diabetes mellitus type 1 (ESPE-ESE 2025) - "Treatment with lifestyle modification—diet to reduce weight, with basal insulin detemir and metformin—was recommended. The patient will continue to be under diabetologist care since her diagnosis of diabetes mellitus type 1 is established, and insulin treatment is expected to be necessary again once the honeymoon period passes. We present this case since it is not usual for obese adult women with prior GDM and a family history of type 2 diabetes mellitus to develop type 1 DM and even less often to develop complete remission shortly after delivery and pregnancy."

Clinical • Diabetes • Hypoglycemia • Metabolic Disorders • Obesity • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus in Teenagers – A Growing Concern for Armenia (ESPE-ESE 2025) - "Laboratory findings confirmed the diagnosis of T2DM: Fasting glucose: 28.7 mmol/L HbA1C: 11.0% C-peptide: 2.6 ng/mL Ketones: 3+ (indicating ketosis) Autoantibodies: Anti-GAD, IgG – 46.6 (>N) Anti-IA-2- 180.59 (>N) Anti-insulin, IgG – 10.13 (N) The patient’s treatment regimen included diet therapy (25 kcal/kg/day), insulin therapy (NovoRapid and Levemir), Metformin, and blood glucose monitoring 5-7 times per day. Early diagnosis and intervention, including lifestyle changes and pharmacological treatment, are essential to managing T2DM in teenagers and preventing long-term complications. Given the increasing prevalence of the condition in this age group, it is critical to recognize the early signs and implement appropriate strategies to address this growing public health issue."

Diabetes • Fatigue • Genetic Disorders • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus

Neonatal diabetes mellitus in a boy with Wolfram-like syndrome. (ESPE-ESE 2025) - "He started on a low dose of insulin detemir with a glucose sensor and after a few days the treatment was changed to subcutaneous insulin via a pump at a dose of 0.4U/kg/day, allowing for his discharge... Patients with Wolfram-like syndrome can develop diabetes mellitus before the age of 6 months. Glucose levels should be evaluated regularly."

CNS Disorders • Diabetes • Epilepsy • Metabolic Disorders • Nephrology • Ocular Inflammation • Otorhinolaryngology

Afrezza® INHALE-1 Study in Pediatrics (clinicaltrials.gov) - P3 | N=319 | Completed | Sponsor: Mannkind Corporation | Active, not recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Pediatrics • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study. (PubMed, J Health Econ Outcomes Res) - "Objective: To examine healthcare resource utilization and costs related to falls/fractures in people with type 2 diabetes treated with the longer-acting basal insulin Gla-300 (insulin glargine 300 U/mL) vs long-acting basal insulins (insulin glargine 100 U/mL or insulin detemir)/neutral protamine Hagedorn (NPH). This retrospective study of Optum's de-identified Clinformatics® Data Mart Database compared data for people aged 50 years or older with at least 1 prescription claim for basal insulin (excluding insulin degludec) between April 1, 2015, and April 30, 2021, who initiated Gla-300 insulin (basal insulin-naive) or transitioned to Gla-300 from a different basal insulin (basal insulin-switch)...Costs tended to be lower for people who switched to Gla-300; however, low event rates caused variability. The results of this study suggest that there is a positive correlation between fall/fracture events and hypoglycemia in people with type 2 diabetes and also, that..."

HEOR • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Type 2 Diabetes Mellitus

Role of Omnipod 5 Automated Insulin Infusion on Glucose Management in Patient with Anti-Insulin Antibodies (ENDO 2025) - "Previous management included metformin, Humalog 16 units before each meal, and Levemir 39 units at night. We believe this demonstrates successful management of the rare disorder of insulin autoimmune syndrome with the use of HumuLIN R U-200 insulin through Insulin Pump. Through multiple medication and treatment adjustments this patient's case shows an improvement over the course of treatment that can be used for future tests and trials.*. .*"

Clinical • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Hypoglycemia • Immunology • Metabolic Disorders • Obstructive Sleep Apnea • Pain • Rare Diseases • Respiratory Diseases • Sleep Disorder • Type 2 Diabetes Mellitus

EXPRESS: Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus. (PubMed, J Investig Med) - "Moreover, the study group had lower insulin resistance index and higher insulin function index, as well as better quality of life and sleep quality. The incidence of adverse reactions exhibited no difference between the two groups.Insulin detemir + metformin + IAsp is effective in the treatment of T2DM, which can effectively improve insulin function and blood glucose index, reduce BMI and insulin dosage without increasing adverse reactions, and improve quality of life and sleep quality."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa. (PubMed, Cost Eff Resour Alloc) - "The ICERs of long acting insulins were considerably higher than South Africa's indicative cost-effectiveness threshold. The status quo of NPH insulin in the management of T1DM in adults remains the most cost-effective option for the South African public health sector."

HEOR • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus

HEALTHCARE RESOURCE UTILISATION AND CLINICAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES SWITCHING FROM FIRST-GENERATION TO A SECOND-GENERATION BASAL INSULINS: REAL WORLD EVIDENCE (ATTD 2025) - "Background and Aims To understand the Health Care Resource Utilization (HCRU) and clinical outcomes in people in England living with type 2 diabetes mellitus (T2DM) who switched from a 1 st generation (Gen1) basal insulin (BI) to a 2 nd generation BI (glargine 300 U/mL [Gla-300] or degludec [IDeg-100]). Methods Retrospective, observational database study (Clinical Practice Research Datalink [CPRD] Aurum linked to the Hospital Episode Statistics database) in people with T2DM initiated on a Gen1 BI (e.g., glargine 100 U/mL, detemir) and switched to a 2 nd generation BI (Gla-300 or IDeg-100) (index event)...Depending on whether this was primary or secondary care recorded participants receiving Gla-300 compared to IDeg-100 experienced 58-63% (p0.001 – p=0.318) fewer diabetic ketoacidosis-related events. Conclusions In this real-world study, people with T2DM treated with Gla-300 demonstrated lower HCRU (primary care and hospitalization) compared with IDeg-100 among those..."

Clinical • Clinical data • HEOR • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus • GEN1

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients (clinicaltrials.gov) - P2/3 | N=65 | Terminated | Sponsor: University of Minnesota | Completed ➔ Terminated

Trial termination • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Hyperglycemia-related risk factors in enteral nutrition in non-critically ill patients. (PubMed, Endocrinol Diabetes Nutr (Engl Ed)) - "Our study shows a high prevalence of carbohydrate metabolism disorders in hospitalized patients on total EN, with age and duration of nutritional treatment being the main risk factors."

Journal • Observational data • Retrospective data • Diabetes • Metabolic Disorders

Effect of insulin aspart combined with insulin detemir and metformin on islet function in newly diagnosed type 2 diabetes mellitus. (PubMed, J Drug Target) - "Insulin detemir + metformin + IAsp was effective in treating T2DM, significantly enhancing insulin function and blood glucose levels, quality of life, and sleep quality. This combination therapy, though not commonly utilized in newly diagnosed T2DM patients, offers a novel therapeutic approach in clinical practice."

Journal • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials. (PubMed, J Prev Alzheimers Dis) - "This network meta-analysis provides valuable insights into the comparative efficacy and safety of antidiabetic agents in AD. Low-dose insulin detemir demonstrated the most significant cognitive improvement and a moderate effect on reducing Aβ deposition. Metformin emerged as the most effective agent for reducing Aβ levels, though its effects on cognitive function were less pronounced. Safety profiles varied, with liraglutide associated with the highest rate of treatment withdrawals, while pioglitazone demonstrated the lowest incidence of treatment-related discontinuations. These findings support the potential use of antidiabetic agents, particularly insulin detemir, as a therapeutic option for AD, although further studies are needed to confirm their long-term benefits and safety."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Inflammation

Comparing the Efficacy of Various Insulin Types: Pharmacokinetic and Pharmacodynamic Modeling of Glucose Clamp Effects in Healthy Volunteers. (PubMed, J Clin Pharmacol) - "The maximum glucose stimulation ( ) was 163, and the insulin concentration for a half-maximal effect ( ) were 1156 pmol/L for insulin lispro, regular human insulin, neutral protamine hagedorn (NPH) insulin, and insulin glargine; 674 pmol/L for insulin aspart; and 5335 pmol/L for insulin detemir...This mechanism-based glucose-insulin model demonstrated that most insulin analogs exhibit similar receptor- and transporter-related parameters. The model, with specific PK but unified PD parameters, may enable clinical optimization of insulin therapy by highlighting differences in pharmacokinetics and operating common intrinsic glucose utilization parameters."

Journal • PK/PD data • Diabetes • Metabolic Disorders

First Dimension Trap-and-Elute Combined with Second Dimension Reversed-Phase Liquid Chromatography Separation Using a Two-Dimensional-Liquid Chromatography-Tandem Mass Spectrometry System for Sensitive Quantification of Human Insulin and Six Insulin Analogs in Plasma: Improved Chromatographic Resolution and Stability Testing. (PubMed, J Sep Sci) - "Multidimensional chromatography coupled to tandem mass spectrometry (MS/MS), including simple sample preparation with protein precipitation, anion conversion with ammonium hydroxide, and solid-phase extraction using mixed-mode anion exchange in a 96-well plate format, has been validated for rapid simultaneous analysis of human insulin and its six analogs (lispro, glulisine, glargine, degludec, detemir, and aspart) in human plasma. Intra-run precision ranged from 1.1% to 5.7%, inter-run precision from 0.7% to 5.9%, and overall recovery from 96.9% to 114.3%. The validated method has been implemented successfully by the Department of Forensic Medicine at our hospital for the investigation of unexplained deaths."

Journal

Cost-Effectiveness Analysis of Pharmacological Treatment With Insulin and Insulin Analogs for Type 1 and Type 2 Diabetes Mellitus in Colombia. (PubMed, Value Health Reg Issues) - "The results favor the use of analog insulins over human insulins, the former reducing the possibility of acute events and chronic complications to a greater extent."

HEOR • Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus

A short-course of low-dose insulin detemir effectively decreases blood glucose levels in gestational diabetic women undergoing dexamethasone treatment to promote newborn lung maturity. (PubMed, Medicine (Baltimore)) - "We performed a retrospective study and reviewed gestational diabetic women who received an intramuscular dexamethasone injection (6 mg, every 12 hours, 4 times) in our hospital between December 2018 and June 2020. Dexamethasone administration increased the blood glucose levels in the pregnant women with gestational diabetes mellitus. A short-course of low-dose insulin detemir administration effectively lowered the blood glucose levels in these women."

Journal • Retrospective data • Acute Respiratory Distress Syndrome • Diabetes • Gestational Diabetes • Metabolic Disorders • Respiratory Diseases

Oral Anti Diabetic Agents in the Hospital (clinicaltrials.gov) - P4 | N=260 | Recruiting | Sponsor: Emory University | Trial completion date: Dec 2024 ➔ Jul 2025 | Trial primary completion date: Nov 2024 ➔ Jul 2025

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders

Safety and Effectiveness of Glargine 300 U/ml After Switching from Basal Insulins in Patients with Type 1 Diabetes: COMET-T Study. (PubMed, Diabetes Ther) - "Although switching to Gla-300 in poorly controlled PwT1D did not significantly reduce TIR, it significantly decreased HbA1c values and glycemic variability without changes in BW and basal insulin dose."

Journal • Diabetes • Metabolic Disorders • Severe Hypoglycemia • Type 1 Diabetes Mellitus

Safety and efficacy of different basal insulin in type 2 diabetes mellitus with chronic kidney disease in Ramadan: prospective observational study. (PubMed, BMC Endocr Disord) - "This study revealed that Insulatard, Levemir, and Glargine demonstrated similar levels of safety and efficacy among those with diabetic kidney disease who observed fasting during Ramadan."

Journal • Observational data • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • MIR34A

Medication Use Evaluation of the Impact of Nursing Education on the Administration of Insulin Detemir in NPO Patients (ASHP 2024) - No abstract available

Clinical

START2: Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) (clinicaltrials.gov) - P=N/A | N=430 | Recruiting | Sponsor: Thomas Jefferson University | Not yet recruiting ➔ Recruiting | Initiation date: May 2024 ➔ Sep 2024

Enrollment open • Trial initiation date • Diabetes • Gestational Diabetes • Metabolic Disorders

START 1: Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (clinicaltrials.gov) - P=N/A | N=430 | Recruiting | Sponsor: Thomas Jefferson University | Not yet recruiting ➔ Recruiting | Initiation date: May 2024 ➔ Sep 2024

Enrollment open • Trial initiation date • Diabetes • Gestational Diabetes • Metabolic Disorders